Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy-Reference-Cited by-同舟云学术

Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy

Published:2004-03-02 Issue:6 Volume:43 Page:704-711
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Cohen S. B.,Strand V.,Aguilar D.,Ofman J. J.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/43/6/704/9445291/keh152.pdf

Reference22 articles.

1. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

2. The links between joint damage and disability in rheumatoid arthritis

3. Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate

4. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis

5. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physician estimate of inflammation vs global assessment in explaining variations in swollen joint counts in rheumatoid arthritis patients;Rheumatology Advances in Practice;2024-01-01

2. Investigation of changes in ankylosing spondylitis disease activity through 2021 COVID-19 wave in Taiwan by using electronic medical record management system;Scientific Reports;2023-01-07

3. Guidelines for Reporting Outcomes in Trial Protocols;JAMA;2022-12-20

4. Expanding Personalized, Data-Driven Dermatology: Leveraging Digital Health Technology and Machine Learning to Improve Patient Outcomes;JID Innovations;2022-05

5. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19;Transplantation;2022-04-26